Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
In plain words A Phase 1 study of trigonelline in people 40 to 70, run by dsm-firmenich Switzerland AG. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 70; healthy volunteers accepted. Conditions: NAD+ Metabolism; Pharmacokinetics; Bioavailability; Healthy Adults.
- Adults who are 40 to 70 years of age (inclusive) at the time of signing the informed consent.
- Are able to consume study product capsules whole without chewing.
- Have suitable veins for repeated venipuncture.
- Non-smokers (including nicotine vaping) and have not used any nicotine products (patches, gums, etc.) for > 3 months prior to Visit 2.
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Mononucleotide (NMN); Placebo; Trigonelline Monohydrate
Registered summary
This Phase 1 study is designed to evaluate the pharmacokinetic, pharmacodynamic, bioavailability, safety, and tolerability effects of trigonelline monohydrate in generally healthy adults aged 40 to 70 years. Sixty participants will be randomized in a double-blind, parallel-arm study to receive one of four doses of trigonelline monohydrate (equivalent to 150 mg, 300 mg, 450 mg, or 600 mg of trigonelline daily), an active comparator (600 mg nicotinamide mononucleotide \[NMN\]), or placebo for 4 weeks. The full summary is on the listing.
Where, as registered
No US site; Canada (1).